^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYC expression

    i
    Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
    Entrez ID:
    4609
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (A051701) (NCT03984448)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/22/2019
    Primary completion :
    04/01/2028
    Completion :
    04/01/2028
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (NCT03742258)
    Phase 1
    Northwestern University
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/13/2019
    Primary completion :
    03/12/2021
    Completion :
    12/19/2028
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    FOG-001 in Locally Advanced or Metastatic Solid Tumors (FOG-001-101) (NCT05919264)
    Phase 1/2
    Fog Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/19/2023
    Primary completion :
    04/01/2027
    Completion :
    08/31/2027
    MSI • CTNNB1
    |
    MYC expression
    |
    FOG-001
    A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma (GO43075) (NCT04980222)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    03/22/2022
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    MYC • BCL2 • CD20 • BCL6
    |
    CD20 positive • MYC expression • BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • cyclophosphamide intravenous
    Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma (NCT06357338)
    Phase N/A
    Marwa Mahmoud Hassan
    Enrolling by invitation
    Last update posted :
    04/10/2024
    Initiation :
    03/19/2024
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    MYC
    |
    MYC expression
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267)
    Phase 2
    Barbara Ann Karmanos Cancer Institute
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    08/21/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2026
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • cyclophosphamide intravenous • methylprednisolone sodium succinate • prednisolone
    A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma (NCT05358379)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    04/14/2022
    Primary completion :
    08/01/2025
    Completion :
    11/01/2025
    PLK1 • CDKN1A
    |
    MYC expression
    CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) (NCT03287817)
    Phase 1/2
    Autolus Limited
    Completed
    Last update posted :
    01/08/2024
    Initiation :
    09/05/2017
    Primary completion :
    12/06/2023
    Completion :
    12/06/2023
    MYC • BCL2 • BCL6
    |
    MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    Keytruda (pembrolizumab) • cyclophosphamide • AUTO3
    Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087)
    Phase 1
    Lapo Alinari
    Recruiting
    Last update posted :
    12/29/2023
    Initiation :
    03/06/2023
    Primary completion :
    03/05/2027
    Completion :
    03/05/2027
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation
    |
    tegavivint (BC2059)
    R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma (NCT04214626)
    Phase 2
    Henan Cancer Hospital
    Active, not recruiting
    Last update posted :
    12/05/2023
    Initiation :
    01/02/2020
    Primary completion :
    11/29/2023
    Completion :
    01/02/2025
    MYC • BCL2
    |
    BCL2 expression • MYC expression • TP53 expression
    |
    Rituxan (rituximab) • lenalidomide • cyclophosphamide • epirubicin • vincristine • prednisone • cyclophosphamide intravenous